首页> 外文会议>Conference on single-use technologies II: bridging polymer science to biotechnology applications >DEVELOPMENT OF AN N-1 PERFUSION PROCESS AND OPTIMIZED SCALE-DOWN MODELS FOR IMPLEMENTATION IN A PLATFORM CHO CELL CULTURE MANUFACTURING PROCESS
【24h】

DEVELOPMENT OF AN N-1 PERFUSION PROCESS AND OPTIMIZED SCALE-DOWN MODELS FOR IMPLEMENTATION IN A PLATFORM CHO CELL CULTURE MANUFACTURING PROCESS

机译:N-1灌注过程的开发和优化的按比例缩小模型,可在平台CHO细胞培养生产过程中实施

获取原文

摘要

The use of N-1 perfusion, coupled with high-inoculum fed batch in CHO cell culture manufacturing processes, has been shown to increase volumetric productivity and shorten the duration of the fed-batch production phase. Implementation of N-1 perfusion as part of a platform process requires the ability to screen multiple clones and to optimize media and process parameters in a high-throughput manner. We have developed an N-1 perfusion process, along with a series of scale-down models for N-1 perfusion using shake flasks, cell culture tubes, and deep-well plates. Process parameters for scale-down models were optimized to maximize comparability of growth profiles and cell culture performance relative to 5L N-1 perfusion bioreactors. Scale-down models were used to inoculate fed-batch experiments in Ambr15 micro-bioreactors at high seeding density, in order to compare growth and productivity profiles to those observed in 5L bench scale bioreactors. Multiple cell lines derived from different CHO hosts were evaluated in order to verify the robustness of the scale-down models. Results demonstrated that cell growth and viability in the optimized scale-down models were comparable to those observed in 5L N-1 perfusion bioreactors. Furthermore, growth, productivity, and product quality profiles from high-inoculum fed-batch experiments were comparable regardless of inoculum source. Optimized scale down models of N-1 perfusion, coupled with Ambr15 fed-batch production micro-bioreactors, have now been integrated into a high-throughput and robust workflow to enable DOE and screening experiments for clone selection, media development and parameter optimization in a platform N-1 perfusion process for monoclonal antibody manufacturing.
机译:已证明在CHO细胞培养生产过程中使用N-1灌流结合高接种量的补料批次可以提高容积生产率并缩短补料批次生产阶段的持续时间。将N-1灌注作为平台过程的一部分,要求具有以高通量方式筛选多个克隆并优化培养基和过程参数的能力。我们已经开发了N-1灌注过程,以及一系列使用摇瓶,细胞培养管和深孔板进行N-1灌注的按比例缩小模型。优化了按比例缩小模型的工艺参数,以相对于5L N-1灌注生物反应器最大程度地提高生长曲线和细胞培养性能的可比性。按比例缩小模型用于以高接种密度接种Ambr15微型生物反应器中的补料分批实验,以便将生长和生产力概况与5L台式生物反应器中观察到的进行比较。为了验证按比例缩小模型的鲁棒性,对源自不同CHO宿主的多个细胞系进行了评估。结果表明,优化的按比例缩小模型中的细胞生长和活力与5L N-1灌注生物反应器中观察到的相当。此外,无论接种源如何,高接种量分批实验的生长,生产率和产品质量概况都是可比的。 N-1灌注的按比例缩小的优化模型,再加上Ambr15分批补料生产的微型生物反应器,现已集成到高通量且功能强大的工作流程中,从而可以进行DOE和筛选实验,以进行克隆选择,培养基开发和参数优化。 N-1灌注平台用于单克隆抗体生产。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号